Navigation Links
NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting
Date:10/13/2008

hich have previously been presented from this trial. This hypothesis will be tested in the ongoing multicenter Phase III registration trial."

Dr. Brown's analysis examined over 1400 images from patients enrolled in the company's ongoing Phase II pilot study, which includes 34 trial participants (with a mean age of 72 years) treated from June 2006 to April 2007 at two centers in Brazil and one in Mexico. These patients, with predominantly classic, minimally classic, or occult (with no classic) choroidal neovascularization (CNV), received a single 24 Gy treatment of NeoVista's epiretinal brachytherapy in combination with two intravitreal injections of an anti-VEGF agent (bevacizumab), which are delivered to maximize the acute therapeutic response. Preliminary data show that NeoVista's targeted radiation therapy is well tolerated and may provide a new approach to restore the patient's vision and improve their quality of life.

"Dr. Brown's analysis is providing valuable information on our novel technology," said John N. Hendrick, President and CEO of NeoVista. "For someone with his credibility and expertise in the field of retinal medicine to independently analyze and present this data is quite encouraging and provides further proof of concept of our technique. We know that the mechanism of action of radiation is different from any therapy currently available for wet AMD and we look forward to the potential promise of significantly decreasing the burden of wet AMD therapy."

The observational analysis was presented at ASRS while NeoVista continues to enroll patients in the company's pivotal Phase III trial, CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy). CABERNET is a multicenter, randomized, controlled study that will enroll 450 subjects at 45 sites worldwide, evaluating the safety and efficacy of NeoVista's epiretinal brachytherapy delivered concomitantly with the FDA-approved anti-VEGF therapy Lucentis(R) (ranibizum
'/>"/>

SOURCE NeoVista, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer
2. The Lewin Group Presents McCain and Obama Health Policies: Cost and Coverage Compared Analysis
3. Stater Bros. Markets Presents $1,143,000 Check to Muscular Dystrophy Association
4. Curemark CEO Presents Autism Findings at Prestigious Neurobiology Conference at Oxford
5. AMA Foundation Presents the Arthur N. Wilson, MD Scholarship to Promising Medical Student From Southeast Alaska
6. USA-ONE Interactive Presents a Free Webinar Series Introducing Docuvation – An Online Document Management Solution
7. AMA Foundation Presents $10,000 Scholarships to Promising Medical Students
8. Neurotherapeutics presents special issue on new treatments for Alzheimers disease
9. Vertos Medical Inc. Presents Clinical Data of its MILD™ Procedure at the 5th Annual Innovative Techniques in Spine Surgery Conference in Los Cabos, Mexico
10. Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapest, Hungary
11. ExonHit Presents Therapeutic and Diagnostic Programs for Alzheimers at ICAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 02, 2015 First Choice Emergency ... rooms in the United States, named Kenneth Alan Totz, ... Jones Road facility. , “We are pleased to ... Road facility,” said Dr. James M. Muzzarelli, Executive Medical ... Totz received his undergraduate degree from St. Edwards University ...
(Date:6/2/2015)... Amercanex, the American Cannabis Exchange, ... become Amercanex’s new Chief Technology Officer. Amercanex is ... cultivators, wholesale distributors and retail vendors can buy, ... transparent intra-state market. , Jim Miller is an ... space, helping innovative technology companies deliver on their ...
(Date:6/2/2015)... 02, 2015 FDA approved Orlistat for ... patients after a satisfactory doctor consultation. The less potent, over-the-counter ... several years and has the longest track record as an ... enzyme that breaks down fats in foods, Orlistat treatment prevents ... intestinal system to be excreted through feces. , ...
(Date:6/2/2015)... Vail, Colorado (PRWEB) June 02, 2015 ... and Chief Medical Officer at the Steadman Philippon Research ... It Too Early for Single Sport Specialization? ” This ... for Sports Medicine (AOSSM) Research Committee that was recently ... the data for this project was limited, there is ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Colleen’s Dream ... has granted $70,000 to the UNMC to support ovarian cancer ... Billy Cundiff, a member of the Colleen’s Dream Foundation Board ... was the biggest to date for Colleen’s Dream Foundation and ... in Omaha. , “Dr. Wang is a rising star in ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Kenneth Alan Totz as New Medical Director of Houston – Jones Road Facility 2Health News:Amercanex Names Jim Miller to CTO Position 2Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 2Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 3Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 4Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 2Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 3Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 3
... drug named bivalirudin is turning out to be a better ... conditions, for instance heart attacks. ,Lead researcher ... of cardiovascular research and education at Columbia University said, "We ... We find that compared to heparin, it is just as ...
... infinite variety', wrote the famous Dramatist and Poet, William Shakespeare ... woman is quite an enigma and undoubtedly, there is more ... 'weaker sex' or the 'fair sex', they often find themselves ... nature has endowed unique qualities in a man and woman, ...
... of 4 cases of botulism following cosmetic injections to ... concentrated, //unlicensed preparation that resulted in toxin levels up ... to a report. ,Botulism is a rare paralytic ... Clostridium botulinum and toxin-producing strains of Clostridium baratii and ...
... to deformities, says a new study. // ,Each ... a large number of ligaments, tendons, blood vessels and nerves ... running. ,Excess weight and obesity can damage ... particular risk of deformities and abnormalities, said Stewart Morrison, a ...
... order to implement better cancer care to patients certain ... published in the British Medical journal. The team of ... Clinical Excellence (NICE) should amend some of their modes ... needs of cancer patients. More planning is essential to ...
... by researchers at Yale School of Medicine has reported about ... aggressive 'wet' form of age-related macular degeneration (AMD), the most ... ,AMD causes light-sensitive cells in the retina to break ... two forms of AMD, the 'dry' is more common than ...
Cached Medicine News:Health News:Men are from Mars and Women from Venus, but why on Earth are Women so Woefully Wronged? 2Health News:Men are from Mars and Women from Venus, but why on Earth are Women so Woefully Wronged? 3Health News:Highly-Concentrated Botulinum Preparation Can Result in Severe Illness 2Health News:Highly-Concentrated Botulinum Preparation Can Result in Severe Illness 3Health News:Cancer Care Compromised by Cost 2Health News:Gene Linked With Aggressive 'Wet' Form Of AMD 2
(Date:6/2/2015)... A new report by the Global Sanitation ... across 13 countries bring an end to open defecation. ... Progress Report details how its financial support for nationally-led ... communities become open-defecation free, improved toilets for 4.2 million ... hand-washing facilities. The Progress Report highlights cumulative ...
(Date:6/2/2015)... June 2, 2015 ... mejora  de 7,9 meses en la supervivencia libre ... con cáncer colorrectal metastático inoperable (mCRC) tratados  en ... Y-90 más quimioterapia    Los beneficios ... directamente al hígado con la quimioterapia sistémica actual ...
(Date:6/2/2015)... CHICAGO e MADRID , ... orale (abstract 10503) al meeting annuale della American Society ... i dati dello studio multicentrico di fase 3 SAR3007, ... Janssen , LLC (Janssen), hanno evidenziato un significativo miglioramento ... con trabectedina (YONDELIS ® ) rispetto al trattamento con ...
Breaking Medicine Technology:Global Sanitation Fund Reports Major Sanitation & Hygiene Advances for Seven Million People in 13 Countries 2Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 2Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 3Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 4Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 5Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 6Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 7Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 8PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 2PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 3PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 4PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 5PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 6
... Loss, Lower Blood Sugar and Improved A1CHORSHAM, Pa., April 21 ... loss program that delivers to your door, today announced the ... specifically for the approximately 24 million Americans with diabetes, as ... for diabetes. In a clinical study at Temple ...
... clinical trial strategies for personalized approach to cancer ... a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) ... preclinical study, which utilized RNA interference (RNAi) and ... vulnerability" - that enhance the anti-tumor response to ...
Cached Medicine Technology:New Weight Loss Hope for People with Diabetes 2New Weight Loss Hope for People with Diabetes 3New Weight Loss Hope for People with Diabetes 4New Weight Loss Hope for People with Diabetes 5New Weight Loss Hope for People with Diabetes 6Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 2Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 4
... developed in surgeon's desire to have the ... instrument with the strength to maneuver into ... bending or breaking. Arthrotek Hand Instruments are ... the surgeon's hand. This new generation of ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
Medicine Products: